Alladapt touts data on food allergy drug as it preps for PhIII

Alladapt Immunotherapeutics said its food allergy drug helped children consume more of what they’re allergic to in a clinical trial, according to results presented on Sunday. Next, the Menlo Park, CA-based biotech is gearing up for a Phase III trial of its oral immunotherapy.

In a Phase I/II study with…

Advertisement — Advertise with Biotech Networks